Uganda

Population 2018  43 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>86 (50–130)</td>
<td>200 (118–304)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>34 (20–52)</td>
<td>81 (47–123)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>1.5 (0.82–2.3)</td>
<td>3.5 (1.9–5.4)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>8.6 (4.8–14)</td>
<td>20 (11–32)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>11 (6.4–16)</td>
<td>25 (15–38)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases 1% (0.91–1.2)
- Previously treated cases 12% (6.5–19)

TB case notifications, 2018
- Total new and relapse 56 835
  - % tested with rapid diagnostics at time of diagnosis 46%
  - % with known HIV status 98%
  - % pulmonary 93%
  - % bacteriologically confirmedººº 56%
  - % children aged 0-14 years 12%
  - % women 31%
  - % men 57%

Total cases notified 57 756

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018 65% (43–110)
- TB patients facing catastrophic total costs, 2017 53% (50–56)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 24% (12–38)

TB/HIV care in new and relapse TB patients, 2018
- Patients with known HIV status who are HIV-positive 22 085 40%
  - on antiretroviral therapy 21 522 97%

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistanceººº
  - New cases 87%
  - Previously treated cases 58%

Laboratory-confirmed cases* MDR/RR-TB: 516, XDR-TB: 9
- Patients started on treatment** MDR/RR-TB: 505, XDR-TB: 5
- MDR/RR-TB cases tested for resistance to second-line drugs 159

Treatment success rate and cohort size
- New and relapse cases registered in 2017 72% 45 099
- Previously treated cases, excluding relapse, registered in 2017 67% 1 825
- HIV-positive TB cases registered in 2017 69% 1 810
- MDR/RR-TB cases started on second-line treatment in 2016 64% 364
- XDR-TB cases started on second-line treatment in 2016 0% 4

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 15% (14–16)

TB financing, 2019
- National TB budget (US$ millions) 37
  - Funding source: 5% domestic, 56% international, 39% unfunded

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2020-04-12 Data: www.who.int/tb/data